Titre : Benzofuranes

Benzofuranes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Autonomous Vehicles
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzofuranes : Questions médicales les plus fréquentes", "headline": "Benzofuranes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzofuranes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-05", "dateModified": "2025-04-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzofuranes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composés hétérobicycliques", "url": "https://questionsmedicales.fr/mesh/D006574", "about": { "@type": "MedicalCondition", "name": "Composés hétérobicycliques", "code": { "@type": "MedicalCode", "code": "D006574", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Amiodarone", "alternateName": "Amiodarone", "url": "https://questionsmedicales.fr/mesh/D000638", "about": { "@type": "MedicalCondition", "name": "Amiodarone", "code": { "@type": "MedicalCode", "code": "D000638", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.075" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Dronédarone", "alternateName": "Dronedarone", "url": "https://questionsmedicales.fr/mesh/D000077764", "about": { "@type": "MedicalCondition", "name": "Dronédarone", "code": { "@type": "MedicalCode", "code": "D000077764", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.075.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Benzbromarone", "alternateName": "Benzbromarone", "url": "https://questionsmedicales.fr/mesh/D001553", "about": { "@type": "MedicalCondition", "name": "Benzbromarone", "code": { "@type": "MedicalCode", "code": "D001553", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.110" } } }, { "@type": "MedicalWebPage", "name": "Cantharidine", "alternateName": "Cantharidin", "url": "https://questionsmedicales.fr/mesh/D002193", "about": { "@type": "MedicalCondition", "name": "Cantharidine", "code": { "@type": "MedicalCode", "code": "D002193", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.125" } } }, { "@type": "MedicalWebPage", "name": "Citalopram", "alternateName": "Citalopram", "url": "https://questionsmedicales.fr/mesh/D015283", "about": { "@type": "MedicalCondition", "name": "Citalopram", "code": { "@type": "MedicalCode", "code": "D015283", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.187" } } }, { "@type": "MedicalWebPage", "name": "Escitalopram", "alternateName": "Escitalopram", "url": "https://questionsmedicales.fr/mesh/D000089983", "about": { "@type": "MedicalCondition", "name": "Escitalopram", "code": { "@type": "MedicalCode", "code": "D000089983", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.203" } } }, { "@type": "MedicalWebPage", "name": "Fura-2", "alternateName": "Fura-2", "url": "https://questionsmedicales.fr/mesh/D016257", "about": { "@type": "MedicalCondition", "name": "Fura-2", "code": { "@type": "MedicalCode", "code": "D016257", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.250" } } }, { "@type": "MedicalWebPage", "name": "Griséofulvine", "alternateName": "Griseofulvin", "url": "https://questionsmedicales.fr/mesh/D006118", "about": { "@type": "MedicalCondition", "name": "Griséofulvine", "code": { "@type": "MedicalCode", "code": "D006118", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.127.275" } } } ], "about": { "@type": "MedicalCondition", "name": "Benzofuranes", "alternateName": "Benzofurans", "code": { "@type": "MedicalCode", "code": "D001572", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Zhi Xu", "url": "https://questionsmedicales.fr/author/Zhi%20Xu", "affiliation": { "@type": "Organization", "name": "School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, Guizhou, P.R. China." } }, { "@type": "Person", "name": "Wei Zhou", "url": "https://questionsmedicales.fr/author/Wei%20Zhou", "affiliation": { "@type": "Organization", "name": "School of Pharmacy, Guizhou Medical University, Guiyang 550025, Guizhou, P.R. China." } }, { "@type": "Person", "name": "Ashraf A Abbas", "url": "https://questionsmedicales.fr/author/Ashraf%20A%20Abbas", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Faculty of Science, Cairo University Giza 12613 Egypt kmdawood@sci.cu.edu.eg +20-2-35727556 +20-2-35676602." } }, { "@type": "Person", "name": "Kamal M Dawood", "url": "https://questionsmedicales.fr/author/Kamal%20M%20Dawood", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Faculty of Science, Cairo University Giza 12613 Egypt kmdawood@sci.cu.edu.eg +20-2-35727556 +20-2-35676602." } }, { "@type": "Person", "name": "Giovanni Luca Beretta", "url": "https://questionsmedicales.fr/author/Giovanni%20Luca%20Beretta", "affiliation": { "@type": "Organization", "name": "Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Via Amadeo 42, 20133 Milan, Italy." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial.", "datePublished": "2023-05-27", "url": "https://questionsmedicales.fr/article/37245011", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12967-023-04213-4" } }, { "@type": "ScholarlyArticle", "name": "Improvements in pincer nail deformity occur earlier and last longer when acetylcysteine gel is added to an overcurvature-correcting device: Results of a phase 3, multicenter, randomized, vehicle-controlled, investigator-blinded study.", "datePublished": "2023-11-27", "url": "https://questionsmedicales.fr/article/38009825", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/1346-8138.17010" } }, { "@type": "ScholarlyArticle", "name": "Assessing the potential spray drift of a six-rotor unmanned aerial vehicle sprayer using a test bench and airborne drift collectors under low wind velocities: impact of atomization characteristics and application parameters.", "datePublished": "2024-07-19", "url": "https://questionsmedicales.fr/article/39030971", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ps.8334" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate-to-severe facial acne vulgaris: A phase 3, multi-centre, randomized, double-blind, vehicle-controlled study.", "datePublished": "2024-07-01", "url": "https://questionsmedicales.fr/article/38948962", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jdv.20159" } }, { "@type": "ScholarlyArticle", "name": "The impact of transcutaneous electrical acustimulation (TEA) on rectal distension-induced pain in patients with irritable bowel syndrome (IBS)-A study to determine the optimal TEA delivery modalities and effects on rectal sensation and autonomic function.", "datePublished": "2024-04-26", "url": "https://questionsmedicales.fr/article/38671591", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/nmo.14799" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzofuranes", "item": "https://questionsmedicales.fr/mesh/D001572" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzofuranes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzofuranes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzofuranes", "description": "Comment diagnostiquer une intoxication aux benzofuranes ?\nQuels tests sont utilisés pour détecter les benzofuranes ?\nQuels symptômes indiquent une exposition aux benzofuranes ?\nLes benzofuranes sont-ils visibles sur des tests standards ?\nQuel rôle joue l'historique médical dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Autonomous+Vehicles&page=574#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzofuranes", "description": "Quels sont les symptômes courants des benzofuranes ?\nLes benzofuranes provoquent-ils des effets psychologiques ?\nY a-t-il des symptômes cutanés associés aux benzofuranes ?\nLes benzofuranes affectent-ils le système respiratoire ?\nLes symptômes varient-ils selon la dose de benzofuranes ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Autonomous+Vehicles&page=574#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzofuranes", "description": "Comment prévenir l'exposition aux benzofuranes ?\nLes travailleurs doivent-ils être formés sur les benzofuranes ?\nQuelles mesures de sécurité sont recommandées en laboratoire ?\nLes benzofuranes sont-ils réglementés ?\nComment gérer les déchets contenant des benzofuranes ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Autonomous+Vehicles&page=574#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzofuranes", "description": "Quel traitement est recommandé pour l'intoxication aux benzofuranes ?\nDes antidotes existent-ils pour les benzofuranes ?\nComment traiter les symptômes neurologiques causés par les benzofuranes ?\nLes soins d'urgence sont-ils nécessaires pour l'exposition aux benzofuranes ?\nLa décontamination est-elle nécessaire après exposition ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Autonomous+Vehicles&page=574#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzofuranes", "description": "Quelles complications peuvent survenir après exposition aux benzofuranes ?\nLes benzofuranes peuvent-ils causer des maladies chroniques ?\nY a-t-il des effets à long terme des benzofuranes ?\nLes benzofuranes peuvent-ils affecter la reproduction ?\nComment surveiller les complications liées aux benzofuranes ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Autonomous+Vehicles&page=574#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzofuranes", "description": "Qui est à risque d'exposition aux benzofuranes ?\nLes benzofuranes sont-ils présents dans des produits courants ?\nL'âge influence-t-il la sensibilité aux benzofuranes ?\nLes antécédents médicaux augmentent-ils le risque ?\nLes benzofuranes affectent-ils différemment les sexes ?", "url": "https://questionsmedicales.fr/mesh/D001572?mesh_terms=Autonomous+Vehicles&page=574#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intoxication aux benzofuranes ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'exposition et les tests toxicologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les benzofuranes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses de sang et d'urine peuvent être effectuées pour détecter ces composés." } }, { "@type": "Question", "name": "Quels symptômes indiquent une exposition aux benzofuranes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles neurologiques, des nausées et des palpitations." } }, { "@type": "Question", "name": "Les benzofuranes sont-ils visibles sur des tests standards ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, des tests spécifiques sont nécessaires pour détecter les benzofuranes." } }, { "@type": "Question", "name": "Quel rôle joue l'historique médical dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique médical aide à établir un lien entre les symptômes et l'exposition aux benzofuranes." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des benzofuranes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des vertiges, des maux de tête et des troubles de la vision." } }, { "@type": "Question", "name": "Les benzofuranes provoquent-ils des effets psychologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent causer de l'anxiété, des hallucinations et des troubles de l'humeur." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés aux benzofuranes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées et des démangeaisons peuvent survenir après exposition." } }, { "@type": "Question", "name": "Les benzofuranes affectent-ils le système respiratoire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent provoquer des difficultés respiratoires et une irritation des voies respiratoires." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon la dose de benzofuranes ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la gravité des symptômes dépend de la dose et de la durée d'exposition." } }, { "@type": "Question", "name": "Comment prévenir l'exposition aux benzofuranes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire." } }, { "@type": "Question", "name": "Les travailleurs doivent-ils être formés sur les benzofuranes ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une formation sur les risques et les mesures de sécurité est essentielle." } }, { "@type": "Question", "name": "Quelles mesures de sécurité sont recommandées en laboratoire ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des hottes, des gants et des lunettes de protection lors de la manipulation." } }, { "@type": "Question", "name": "Les benzofuranes sont-ils réglementés ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, leur utilisation est souvent réglementée en raison de leur toxicité potentielle." } }, { "@type": "Question", "name": "Comment gérer les déchets contenant des benzofuranes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les déchets doivent être éliminés selon les protocoles de gestion des déchets dangereux." } }, { "@type": "Question", "name": "Quel traitement est recommandé pour l'intoxication aux benzofuranes ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement comprend l'élimination de l'exposition et des soins symptomatiques." } }, { "@type": "Question", "name": "Des antidotes existent-ils pour les benzofuranes ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas d'antidote spécifique pour les benzofuranes." } }, { "@type": "Question", "name": "Comment traiter les symptômes neurologiques causés par les benzofuranes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments peuvent être prescrits pour gérer les symptômes neurologiques." } }, { "@type": "Question", "name": "Les soins d'urgence sont-ils nécessaires pour l'exposition aux benzofuranes ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des soins d'urgence peuvent être nécessaires en cas d'exposition sévère." } }, { "@type": "Question", "name": "La décontamination est-elle nécessaire après exposition ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la décontamination est essentielle pour réduire l'absorption des benzofuranes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après exposition aux benzofuranes ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques, respiratoires et dermatologiques peuvent survenir." } }, { "@type": "Question", "name": "Les benzofuranes peuvent-ils causer des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Une exposition prolongée peut augmenter le risque de maladies chroniques." } }, { "@type": "Question", "name": "Y a-t-il des effets à long terme des benzofuranes ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets à long terme incluent des troubles cognitifs et des problèmes respiratoires." } }, { "@type": "Question", "name": "Les benzofuranes peuvent-ils affecter la reproduction ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent qu'ils peuvent avoir des effets néfastes sur la reproduction." } }, { "@type": "Question", "name": "Comment surveiller les complications liées aux benzofuranes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi médical régulier est recommandé pour détecter les complications précoces." } }, { "@type": "Question", "name": "Qui est à risque d'exposition aux benzofuranes ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs en laboratoire et ceux manipulant des produits chimiques sont à risque." } }, { "@type": "Question", "name": "Les benzofuranes sont-ils présents dans des produits courants ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être présents dans certains produits chimiques et médicaments." } }, { "@type": "Question", "name": "L'âge influence-t-il la sensibilité aux benzofuranes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées peuvent être plus sensibles." } }, { "@type": "Question", "name": "Les antécédents médicaux augmentent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies respiratoires ou neurologiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les benzofuranes affectent-ils différemment les sexes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que les effets peuvent varier entre les sexes, mais les données sont limitées." } } ] } ] }

Sources (5748 au total)

Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial.

Glioblastoma multiforme (GBM) is associated with remarkably poor prognosis, and its treatment is challenging. This investigation aimed to evaluate the safety of suicide gene therapy using allogeneic a... This study was a first-in-human, open-label, single-arm, phase I clinical trial with a classic 3 + 3 dose escalation design. Patients who did not undergo surgery for their recurrence were included and... A total of 12 patients with recurrent GBM were recruited. The median follow-up was 16 (IQR, 14-18.5) months. This gene therapy protocol was safe and well tolerated. During the study period, eleven (91... The present clinical trial, for the first time, showed that suicide gene therapy using allogeneic ADSCs carrying the HSV-TK gene is safe in patients with recurrent GBM. Future phase II/III clinical tr... Iranian Registry of Clinical Trials (IRCT), IRCT20200502047277N2. Registered 8 October 2020, https://www.irct.ir/ ....

Assessing the potential spray drift of a six-rotor unmanned aerial vehicle sprayer using a test bench and airborne drift collectors under low wind velocities: impact of atomization characteristics and application parameters.

The unmanned aerial spraying systems (UASS) have gained widespread use for plant protection in recent years. However, spray drift from UASS is a major concern when controlling weeds over large areas a... Atomization characteristics were significantly affected by the spray liquid, adjuvant, nozzle type and spray pressure. The addition of an adjuvant reduced the liquid sheet length, improved physicochem... The combination of using TB in the target area and ADCs in the off-target area as an alternative method to determine residual droplets in the current airflow provided valuable insights into airborne d...

Efficacy and safety of topical minocycline foam (FMX101 4%) in treatment of Chinese subjects with moderate-to-severe facial acne vulgaris: A phase 3, multi-centre, randomized, double-blind, vehicle-controlled study.

FMX101 4%, as a topical foam formulation of minocycline, has been approved by US Food and Drug Administration for the treatment of moderate-to-severe acne vulgaris (AV).... To evaluate the efficacy and safety of FMX101 4% in treating Chinese subjects with moderate-to-severe facial AV.... This was a multi-centre, randomized, double-blind, vehicle-controlled phase 3 study in Chinese subjects with moderate-to-severe AV. Eligible subjects were randomized 2:1 to receive either FMX101 4% or... In total, 372 subjects were randomized into two groups (FMX101 4% group, n = 248; vehicle group, n = 124). After 12 weeks treatment, the reduction in ILC from baseline was statistically significant in... FMX101 4% treatment for 12 weeks could lead to significantly reduced ILC and nILC, and improved IGA treatment success rate in Chinese subjects with moderate-to-severe facial AV. It also showed a well ...

The impact of transcutaneous electrical acustimulation (TEA) on rectal distension-induced pain in patients with irritable bowel syndrome (IBS)-A study to determine the optimal TEA delivery modalities and effects on rectal sensation and autonomic function.

Treatment options for abdominal pain in IBS are inadequate. TEA was reported effective treatment of disorders of gut-brain interaction but its mechanism of action and optimal delivery method for treat... Nineteen IBS-C patients underwent TEA at acupoints ST36 (leg), PC6 (wrist), or sham-acupoint. Each patient was studied in five randomized sessions on separate days: (1) TEA/ST36-100 Hz; (2) TEA/ST36-2... Studied patients were predominantly female, young, and Caucasian. Compared with baseline, patients treated with TEA/ST36-100 Hz had significantly decreased pain scores at RD pressure-points 20-50 mmHg... TEA at ST36-100 Hz is superior stimulation point/parameter, compared to TEA at PC-6/sham-TEA, to reduce rectal distension-induced pain in IBS-C patients. This therapeutic effect appears to be mediated...

Effect of a Group-Based Personal Assistive RObot (PARO) Robot Intervention on Cognitive Function, Autonomic Nervous System Function, and Mental Well-being in Older Adults With Mild Dementia: A Randomized Controlled Trial.

PARO interventions have been used to treat agitation and mood symptoms of dementia effectively. However, the effects of a PARO intervention on physiological and cognitive function are unclear. To exam... Using a group-based PARO intervention randomized controlled trial with 2-arm parallel groups.... Older adults with mild dementia aged 65 years or older from 4 dementia day care centers were recruited.... Physiological parameters were assessed using the finger tapping test (FTT) and heart rate variability (HRV). The Mini-Mental State Examination (MMSE), Geriatric Depression Scale-Short Form (GDS-SF), U... Using a repeated-measures generalized linear model, significant time × group interactions were found in the MMSE [F(2, 115) = 19.54, P < .001], FTT [F(2, 115) = 4.87, P = .01], HRV high-frequency [F(2... A PARO intervention may effectively improve the physiological and psychological responses of people with mild dementia....

A randomized, observer-blind, vehicle-control, multi-center clinical investigation for assessing the efficacy and tolerability of a 1% ectoine and hyaluronic acid 0.1%-containing medical device in pediatric patients with mild-to-moderate atopic dermatitis.

Ectoine is a widespread osmolyte enabling halophilic bacteria to withstand high osmotic stress that has many potential applications ranging from cosmetics to its use as a therapeutic agent.... The aim of this study was to compare the efficacy and tolerability of ectoine 1% and hyaluronic acid 0.1% containing (EHA) cream with a vehicle cream in children with mild-to-moderate atopic dermatiti... A randomized, controlled, observer-blind, multicenter clinical trial was conducted in children aged 2-18 years, diagnosed with mild-to-moderate AD (SCORAD ≤20). Patients were randomized to either rece... A total of 70 patients (35 in each group) were randomized and 57 were included in the final analysis set. Based on SCORAD measurements, patients using EHA cream achieved superior clinical improvement ... In children 2-18 years old with mild-to-moderate AD, EHA cream was superior to vehicle cream, with minor AEs....

New Diabetic Treatment by Alleviation of Autonomic Nervous System Dysfunction Measured as Periosteal Pressure Sensitivity at Sternum Improves Empowerment, Treatment Satisfaction, and Self-Reported Health of People with Type 2 Diabetes: A Randomized Trial.

Autonomic nervous system dysfunction (ANSD), for which presently no treatment exists, has a negative impact on prognosis in people with type 2 diabetes (T2D). Periosteal pressure sensitivity (PPS) on ... Analysis of secondary endpoints in a single center, two-armed, parallel-group, observer-blinded, randomized controlled trial of individuals with T2D. Participants were randomized to non-pharmacologica... We included 144 participants, 71 allocated to active intervention and 73 to the control group. Active intervention compared to control revealed improved diabetes-specific empowerment (p = 0.004), DTSQ... This non-pharmacological intervention, aiming to reduce PPS, and thus ANSD, improved diabetes-specific empowerment, treatment satisfaction, and self-reported health when compared to usual treatment. T...

Early-stage voiding function following uni- versus bilateral inferior vesical vessel resection during therapeutic lateral lymph node dissection with autonomic nerve sparing for advanced low rectal cancer (with video).

Lateral lymph node dissection (LLND) has now been widely accepted as the optimal procedure to minimize lateral local recurrence (LLR) for selected cases with advanced lower rectal cancer in Asian coun... To evaluate the early-stage postoperative voiding function in patients who underwent LLND with uni- versus bilateral resection of the IVVs and to introduce an autonomic nerve sparing technique with a ... LLND was performed in 106 consecutive patients with advanced low rectal cancer at Tianjin Union Medical Center from May 2017 to October 2022. Prospectively collected clinical data were retrospectively... The unilateral lymph node dissection (LND) group and the bilateral LND group included 75 and 31 cases, respectively. All LLNDs were performed with FSPA with IVV resection as a standard procedure. No s... Autonomic nerve sparing is achievable with resection of IVVs during LLND. Satisfactory early-stage voiding function could be obtained with IVV resection on both sides....

Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial.

Corticosteroids are among the few effective treatments for knee osteoarthritis, but short duration of action limits their utility. EP-104IAR, a long-acting formulation of fluticasone propionate for in... SPRINGBOARD was a randomised, vehicle-controlled, double-blind, phase 2 trial done at 12 research sites in Denmark, Poland, and Czech Republic. We recruited adults aged 40 years or older with primary ... Between Sept 10, 2021, and Nov 16, 2022, 1294 people were screened for eligibility, and 319 were randomly assigned to EP-104IAR (n=164) or vehicle control (n=155). One participant in the EP-104IAR gro... These phase 2 results suggest that EP-104IAR has the potential to offer clinically meaningful pain relief in knee osteoarthritis for an extended period of up to 14 weeks, longer than published data fo... Eupraxia Pharmaceuticals.... For the Danish translation of the abstract see Supplementary Materials section....